Hi, I'm Georgie Frost.
I'm here on the ground at the JP Morgan Healthcare Conference in
San Francisco, talking to BCG experts about the innovations
and trends that they're most excited about for 2025.
I think I'm most excited to see the continued
evolution of direct-to-patient therapies.
The development of new platforms
focused on getting therapies into the hands of patients that
might not necessarily have a tremendous amount of access to
those therapies.
We see new platform technologies coming to life,
RLT, the big thing on the oncology side.
I'm excited about personalization.
Next generation sequencing and understanding your
genome or the
DNA of your cancer.
Less innovations on the admin cost side. Less about
how we can really get utilization management to
where it needs to be.
Much more on the medical cost side.
There are finally therapies that work for obesity.
These drugs change people's lives and change
the health of billions of people around the world that can benefit from a
prevention perspective.
We're crossing the chasm on the consumer side and is
a lot of more willingness in terms of adoption, usage.
And that's really what's needed to make sure we get to scalability.
A lot of the applications were much more internally
focused around productivity, but we're now seeing AI and
GenAI start to embed themselves into customer-facing products,
and I think that holds tremendous promise for the industry as a whole.